Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T12:05:30.892Z.
Calculation as of: 2026-10-06T12:05:30.892Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 66e3eaee1cdd755dffe0dd2f4d89b3fc137545160e5faabf240127d9674bae42
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$206.61M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$192.97M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$184.12M
Price/FCF Ratio
N/A
TTM Avg
81.50
3Y Avg
61.57
5Y Avg
61.57
Market Cap
$179.70M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$174.17M
Price/FCF Ratio
N/A
TTM Avg
396.65
3Y Avg
396.65
5Y Avg
396.65
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | $202.05M | N/A | N/A | N/A | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $206.61M | N/A | N/A | N/A | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.97M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $218.42M | N/A | N/A | N/A | N/A |
| Journey Medical Corporation (DERM)vs › | $184.12M | N/A | 81.50 | 61.57 | 61.57 |
| Alector, Inc. (ALEC)vs › | $220.94M | N/A | 3.22 | 3.23 | 4.48 |
| Canton Strategic Holdings Inc (CNTN)vs › | $179.70M | N/A | N/A | N/A | N/A |
| Cue Biopharma, Inc. (CUE)vs › | $176.96M | N/A | N/A | N/A | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $174.17M | N/A | 396.65 | 396.65 | 396.65 |
| Coherus Oncology, Inc. (CHRS)vs › | $173.04M | N/A | 193.13 | 193.13 | 37.96 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
